Taro Pharmaceutical Industries Ltd.

TARO · NYSE
Analyze with AI
3/31/2024
12/31/2023
9/30/2023
6/30/2023
Operating Activities
Net Income$15$20$9$10
Dep. & Amort.$8$7$8$8
Deferred Tax$14$3$0$2
Stock-Based Comp.$0$0$0$0
Change in WC$3$5$30-$9
Other Non-Cash-$10-$4$1-$4
Operating Cash Flow$44$31$48$8
Investing Activities
PP&E Inv.-$8-$34-$7-$7
Net Acquisitions$0$0-$0$0
Inv. Purchases-$2$0$32-$32
Inv. Sales/Matur.-$43$116$74$0
Other Inv. Act.-$51$116$0-$32
Investing Cash Flow-$52$82$99-$39
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0$0$0$0
Forex Effect-$1$1-$1$1
Net Chg. in Cash-$20$113$145-$30
Supplemental Information
Beg. Cash$382$269$124$154
End Cash$363$382$269$124
Free Cash Flow$36-$4$41$1
Taro Pharmaceutical Industries Ltd. (TARO) Financial Statements & Key Stats | AlphaPilot